Clinical Trial Update: A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa [Phase 2]

View source ↗

Summary

Phase 2 study of the Encapsulated Cell Technology Implant for late-stage Retinitis Pigmentosa has completed. Results have been posted by Neurotech Pharmaceutica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• Encapsulated Cell Technology Implant

Snippet

Sponsor: Neurotech Pharmaceuticals | Conditions: Retinitis Pigmentosa | Phase 2 | Status: COMPLETED | Results posted: 2024-08-13